Roth Capital initiated coverage on shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) in a research report released on Thursday, October 19th, MarketBeat Ratings reports. The firm issued a buy rating and a $62.00 target price on the biopharmaceutical company’s stock.
MDGL has been the topic of several other reports. Evercore ISI began coverage on shares of Madrigal Pharmaceuticals in a research report on Friday, September 22nd. They set an outperform rating and a $65.00 target price on the stock. JMP Securities boosted their target price on shares of Madrigal Pharmaceuticals from $40.00 to $63.00 and gave the stock an outperform rating in a research report on Friday, October 13th.
Madrigal Pharmaceuticals (MDGL) traded down $4.70 during trading hours on Thursday, reaching $43.28. 92,386 shares of the company were exchanged, compared to its average volume of 66,998. Madrigal Pharmaceuticals has a 1 year low of $13.09 and a 1 year high of $52.35.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings data on Thursday, August 10th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.09). equities analysts anticipate that Madrigal Pharmaceuticals will post -2.85 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by BBNS and is the property of of BBNS. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://baseballnewssource.com/markets/madrigal-pharmaceuticals-inc-mdgl-research-coverage-started-at-roth-capital/1726756.html.
In other news, Director Richard S. Levy purchased 2,000 shares of the business’s stock in a transaction dated Wednesday, August 23rd. The stock was acquired at an average price of $16.12 per share, with a total value of $32,240.00. Following the purchase, the director now directly owns 7,200 shares of the company’s stock, valued at approximately $116,064. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Richard S. Levy purchased 3,550 shares of the business’s stock in a transaction dated Tuesday, August 22nd. The shares were purchased at an average cost of $16.12 per share, with a total value of $57,226.00. Following the purchase, the director now directly owns 3,640 shares in the company, valued at $58,676.80. The disclosure for this purchase can be found here. Insiders have bought a total of 9,100 shares of company stock valued at $145,840 in the last ninety days. Corporate insiders own 66.40% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC raised its stake in Madrigal Pharmaceuticals by 0.7% in the 1st quarter. Renaissance Technologies LLC now owns 57,875 shares of the biopharmaceutical company’s stock valued at $891,000 after purchasing an additional 400 shares during the last quarter. Victory Capital Management Inc. acquired a new position in Madrigal Pharmaceuticals in the 3rd quarter valued at about $2,274,000. Northern Trust Corp raised its stake in Madrigal Pharmaceuticals by 151.2% in the 2nd quarter. Northern Trust Corp now owns 50,069 shares of the biopharmaceutical company’s stock valued at $814,000 after purchasing an additional 30,134 shares during the last quarter. State Street Corp acquired a new position in Madrigal Pharmaceuticals in the 2nd quarter valued at about $539,000. Finally, Shikiar Asset Management Inc. raised its stake in Madrigal Pharmaceuticals by 52.8% in the 3rd quarter. Shikiar Asset Management Inc. now owns 23,141 shares of the biopharmaceutical company’s stock valued at $1,041,000 after purchasing an additional 8,000 shares during the last quarter. 16.86% of the stock is owned by hedge funds and other institutional investors.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Receive News & Ratings for Madrigal Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.